市場調查報告書
商品編碼
1577005
細胞與基因治療製造服務市場、機會、成長動力、產業趨勢分析與預測,2024-2032Cell and Gene Therapy Manufacturing Services Market, Opportunity, Growth Drivers, Industry Trend Analysis and Forecast, 2024-2032 |
受細胞和基因療法進步以及臨床試驗數量不斷增加的推動,全球細胞和基因療法製造服務市場到 2023 年價值 59 億美元,2024 年至 2032 年複合年成長率將擴大到 18.9%。基因編輯和細胞治療的創新正在擴大治療的可能性,增加對專業製造的需求。此外,新療法臨床試驗的增加增加了對可擴展且合規的製造解決方案的需求。技術進步和積極的臨床研究的結合將促進市場成長並推動對先進製造服務的需求。
整個細胞和基因治療製造服務行業根據類型、適應症、模式、最終用戶和地區進行分類。
細胞治療領域在 2023 年佔據 60.6% 的佔有率,並且在其廣泛應用和持續進步的推動下,到 2032 年將以 18.6% 的複合年成長率成長。隨著包括 CAR-T 和幹細胞治療在內的細胞療法在治療各種疾病方面獲得越來越多的關注,對專業製造服務的需求也在增加。細胞療法所需的複雜性和客製化推動了對複雜製造流程的需求。隨著不斷的創新和越來越多的臨床應用,細胞治療領域將引領市場。
憑藉其成本效益和專業知識,到 2032 年,合約製造領域的價值將達到 213 億美元。合約製造組織 (CMO) 提供專業服務,滿足細胞和基因療法從生產到品質控制的複雜且可擴展的需求。他們提供先進技術和監管合規性的能力,以及擴大營運規模的靈活性,使他們成為治療開發商的重要合作夥伴。隨著對這些療法的需求成長,合約製造領域將主導市場。
由於其先進的醫療基礎設施、對生物技術的大量投資以及領先的製藥和生物技術公司的高度集中,到 2032 年,北美的複合年成長率將達到 18.1%。該地區健全的監管環境和強大的研發能力進一步鞏固了其地位。隨著對尖端療法的需求不斷成長,北美現有的專業知識和資源使其成為全球細胞和基因療法製造服務市場的重要貢獻者。
The Global Cell & Gene Therapy Manufacturing Services Market, worth USD 5.9 billion in 2023, will expand to an 18.9% CAGR from 2024 to 2032, driven by advancements in cell and gene therapies and the growing number of clinical trials. Innovations in gene editing and cell-based treatments are expanding therapeutic possibilities, increasing demand for specialized manufacturing. Additionally, the rise in clinical trials for new therapies amplifies the need for scalable and compliant manufacturing solutions. This combination of technological progress and active clinical research will boost market growth and drive the demand for advanced manufacturing services.
The overall cell & gene therapy manufacturing services industry is segregated based on type, indication, mode, end use r, and region.
The cell therapy segment captured a 60.6% share in 2023 and will grow at an 18.6% CAGR through 2032, spurred by its widespread application and ongoing advancements. As cell therapies, including CAR-T and stem cell treatments, gain traction in treating various conditions, the demand for specialized manufacturing services increases. The complexity and customization required for cell therapies drive the need for sophisticated manufacturing processes. With continuous innovation and a growing number of clinical applications, the cell therapy segment will lead the market.
The contract manufacturing segment will reach USD 21.3 billion by 2032, attributed to its cost-effectiveness and expertise. Contract manufacturing organizations (CMOs) offer specialized services that address the complex and scalable needs of cell and gene therapies, from production to quality control. Their ability to provide advanced technologies and regulatory compliance, along with the flexibility to scale operations, makes them essential partners for therapy developers. As demand for these therapies grows, the contract manufacturing segment will dominate the market.
North America will register an 18.1% CAGR through 2032 due to its advanced healthcare infrastructure, significant investments in biotechnology, and a high concentration of leading pharmaceutical and biotech companies. The region's robust regulatory environment and strong research and development capabilities further bolster its position. As the demand for cutting-edge therapies grows, North America's established expertise and resources make it a crucial contributor to the global cell & gene therapy manufacturing services market.